The horizontal bars indicate the median values of each group. cellular infiltration in the interstitium and perivascular regions were significantly less severe in the EA extract treated mice than in vehicle treated mice. Treatment with the EA extract significantly inhibited the progression of kidney disease in NZB/W F1 mice, though had no significant effect on the levels of anti-dsDNA antibody. Introduction The Chinese anti-rheumatic remedy Tripterygium wilfordii Hook F (TwHF) has been reported to be effective in the treatment of a variety of autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis [1,2]. Cefmenoxime hydrochloride The therapeutic benefit of TwHF preparations in patients with a variety of kidney diseases, including IgA nephropathy and Henoch-Schonlein purpura nephritis, has also been described [3-6]. Moreover, in several uncontrolled trials, improvement in clinical manifestations and laboratory abnormalities was observed in as many as 94% of SLE patients treated with a variety of TwHF preparations [7-10]. Different preparations of TwHF have been tested for their therapeutic effect in the MRL-lpr/lpr murine model of lupus. The TwHF preparations employed in these studies Cefmenoxime hydrochloride were crude extracts and their composition was not known. Therefore, it is difficult to assess the pharmacological impact of the material or to standardize the extract for further development. Gu and colleagues Cefmenoxime hydrochloride [11] found that a water extract of Rabbit polyclonal to ACBD6 TwHF ameliorated glomerulonephritis and prolonged survival in MRL-lpr/lpr mice, but only when therapy was begun before disease onset. Consistent with this, Zhang and colleagues [12] reported improvement in survival, proteinuria, arthritis and lymphadenopathy in MRL-lpr/lpr mice treated with another TwHF preparation. However, no improvement in renal histology was noted. Although both of these studies suggest benefit in this model of murine lupus when treatment was begun before disease onset, the full extent of potential benefit was not established. Importantly, no evidence was provided that the extract of TwHF was beneficial as treatment after onset of autoimmune disease. NZB/W F1 mice spontaneously develop autoantibodies against double-stranded (ds)DNA; these antibodies form immune complexes with dsDNA. Deposition of the immune complex in the kidney induces activation of the complement system, which consequently results in chronic glomerulonephritis, vasculitis and cellular infiltration in the interstitium of the kidney [13,14]. This animal model has been commonly used for screening of drugs for treatment of human SLE because of its similarities to human SLE in clinical, immunopathological, and genetic features [15-18]. Specifically, the high incidence of SLE-like disease, characterized by gender selectivity, chronic immune complex nephritis and high titers of anti-dsDNA Cefmenoxime hydrochloride antibody, makes it possible to evaluate efficacy of treatment easily in the NZB/W F1 mice. This animal model, however, had not yet been employed to assess the impact of the TwHF preparations. An ethyl acetate (EA) extract of TwHF has been prepared and used for the first time in the United States in a controlled, double-blinded clinical trial of patients with RA [19,20]. Results from the trial showed significant therapeutic benefit and good tolerance in treated RA patients. The EA extract of TwHF has been studied in detail for its content of active components, namely the diterpenoids, triptolide and tripdiolide, as well as its in vitro and in vivo anti-inflammatory and immunosuppressive impact and toxicity [21-25]. Importantly, the EA extract of TwHF can be standardized by quantitatively assessing its content of active components, as well as Cefmenoxime hydrochloride with regard to efficacy and adverse events. To estimate the potential therapeutic effect of this standardized extract on patients with SLE, experiments with NZB/W F1 mice.